The vaccination program at Advocate Condell Medical Center in Libertyville, Illinois, said it would restart vaccinations for other employees after four workers experienced adverse relations to the vaccine.

“Our site vaccination teams remain prepared to respond quickly and appropriately should anyone experience any kind of reaction,” the hospital statement, according to FOX 32. “Out of an abundance of caution, we have increased our post-vaccine evaluation period to 30 minutes for all individuals across all our sites, which exceeds CDC/ACIP recommendations.”

The medical center noted that the four affected employees represent “only a small fraction” of the organization’s 3,000 employees who have been vaccinated since the Pfizer and BioNTech vaccine became available earlier this week.  But that’s a larger share than those being hospitalized for the disease they are allegedly vaccinating everyone for.

While the medical center — about 39 miles north of Chicago — temporarily paused injections of the Pfizer vaccine at its Libertyville site, the organization’s other sites, including eight more in Illinois and three in Wisconsin, were continuing vaccinations without disruption, officials told FOX 32.

In Alaska, 2 out of about 100 people who were vaccinated had severe adverse reactions.

On Wednesday, state officials in Alaska reported that two health care workers in that state experienced allergic reactions to the Pfizer product.

One worker, described as a middle-aged woman with no previous allergy history, stabilized after treatment Tuesday following a rapid heartbeat, trouble breathing and a skin rash and redness, CBS News reported. She was admitted to a Juneau hospital for monitoring.

The second employee experienced milder symptoms, including eye puffiness, lightheadedness and a scratchy throat, the report said. –FOX 32

Vaccine Trial Participants Warn: Side Effects After Second Shot Are “Intense”

More Side Effects From The Vaccine: Nurse Faints Moments After Getting The Shot

Federal officials have announced agreements for a total of 200 million doses of the Moderna product and 100 million doses of the Pfizer product.